CP Kelco
ATLANTA, 2015-11-19 19:00 CET (GLOBE NEWSWIRE) --
CP Kelco, a leading global producer of specialty hydrocolloid solutions, today announced its intent to build a new state-of-the-art manufacturing plant in North America for gellan gum and specialty xanthan gum.
“In light of the continued increase in global demand for gellan gum and specialty xanthan gum across all regional markets, investing in a new production facility demonstrates our commitment to serve as a sustainable provider and leading innovator of these high-performance products over the long term,” said Don Rubright, President of CP Kelco.
CP Kelco produces gellan gum and specialty xanthan gum for use in a wide range of food, beverage and other applications across both developed economies and emerging markets.
About CP Kelco
Headquartered in Atlanta, Georgia, USA, and part of J.M. Huber Corporation, CP Kelco is a leading producer of specialty hydrocolloids with offices and facilities across the globe. Featuring an extensive range of hydrocolloid solutions and serving over 100 countries, CP Kelco leverages its capabilities to bring concepts and ideas to real-world products in a broad range of applications. The company’s specialty ingredients touch a wide variety of industrial applications, consumer and household products, tailored to meet the needs of regional consumers. Key product lines areGellan Gum,Pectin,Cellulose Gum, Diutan Gum,Xanthan Gum,CarrageenanandMicroparticulated Whey Protein Concentrate, as well as other unique biopolymers. Visitwww.cpkelco.comfor more information.
Michele Cacdac-Jones
Director of Communications
Office: +1 678 247 7149
michele.cacdac-jones@cpkelco.com
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
TCM Group A/S5.8.2025 08:13:25 CEST | Press release
TCM Group A/S: Major shareholder announcement
TCM Group A/S5.8.2025 08:13:25 CEST | Pressemeddelelse
TCM Group A/S: Storaktionærmeddelelse
Tallink Grupp5.8.2025 08:00:44 CEST | Press release
AS Tallink Grupp Statistics for July 2025
ING Group5.8.2025 08:00:00 CEST | Press release
Progress on share buyback programme
Purespring Therapeutics5.8.2025 08:00:00 CEST | Press release
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN)
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom